Evidence map›Paper›PMID 40507156›Full record

ReviewNutrients2025

Critical Review on the Anti-Tumor Activity of Bioactive Compounds from Edible and Medicinal Mushrooms over the Last Five Years.

Sandra Górska-Jakubowska, Yingzi Wu, Jadwiga Turło, Baojun Xu

Abstract readReview
In one paragraph

Review in Nutrients, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Sandra Górska-JakubowskaDepartment of Drug Technology and Pharmaceutical Biotechnology, Medical University of Warsaw, 1 Banacha Str., 02-097 Warsaw, Poland.ORCID 0000-0002-5437-0205
Yingzi WuFood Science and Technology Program, Department of Life Sciences, Beijing Normal-Hong Kong Baptist University, Zhuhai 519087, China.ORCID 0000-0002-6174-0796
Jadwiga TurłoDepartment of Drug Technology and Pharmaceutical Biotechnology, Medical University of Warsaw, 1 Banacha Str., 02-097 Warsaw, Poland.ORCID 0000-0003-3575-8631
Baojun XuFood Science and Technology Program, Department of Life Sciences, Beijing Normal-Hong Kong Baptist University, Zhuhai 519087, China.ORCID 0000-0003-0739-3735

Funding

Beijing Normal-Hong Kong Baptist University UICR0400016-24
6 · The paper itself

Abstract

In recent years, the incidence rate of cancer has been on the rise all over the world, and the age of cancer patients has shown a younger trend, which seriously endangers patients' health. Edible/medicinal mushrooms have not only become a new source of nutritional supplements but have also emerged as a promising adjunct to conventional medicine, either by directly or indirectly killing tumor cells and enhancing immunity, or through their use in conjunction with modern cancer therapies to enhance their efficacy or reduce their side-effects, improving patients' quality of life. Although the anti-cancer potential of edible and medicinal mushrooms has been widely studied in the past, this review focuses on the most recent literature from the last five years, providing an up-to-date and comprehensive summary of the current findings. In this review, we aim to analyze the anti-cancer effects of edible/medicinal mushrooms, including

Indexed as

AgaricalesAntineoplastic AgentsBiological ProductsNeoplasmsAnimalsHumansAntineoplastic AgentsBiological Productsanti-cancer effectbioactive compoundsmechanismmushroom

Identifiers

PMID40507156
PMCPMC12157108

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.